

Douglas A. Craig
Serial No.: 09/450,880
Filed: November 29, 1999
Page 2

In the Claims:

Please amend claims 1, 2, 7, 8, 13, 14, 19, and 20 as follows:

- 1. (Three Times Amended) A method of treating urinary incontinence in a human subject suffering from urinary incontinence which comprises administering to the human subject a therapeutically effective amount of a 5-HT_{1F} receptor agonist which selectively activates the human 5-HT_{1F} receptor.--
- 2. (Amended) The method of claim 1, wherein the 5-HT_{1F} receptor agonist additionally activates the human 5-HT_{1F} receptor at least ten-fold more than it activates any of the human 5-HT_{1B}, 5-HT_{1E}, 5-HT_{2B}, 5-HT_{5A}, 5-HT_{5B}, or 5-HT₆ receptor.--
- 7. (Amended) The method of claim 1, wherein the 5-HT_{1F} receptor agonist activates the human 5-HT_{1F} receptor at least 50-fold more than it activates any of the human 5-HT_{1A}, 5-HT_{1D}, 5-HT_{2A}, 5-HT_{2C}, 5-HT₃, 5-HT₄, or 5-HT₇ receptor.--
- 8. (Amended) The method of claim 7, wherein the 5-HT_{1F} receptor agonist additionally activates the human 5-HT_{1F} receptor at least 50-fold more than it activates any of the human 5-HT_{1B}, 5-HT_{1E}, 5-HT_{2B}, 5-HT_{5A}, 5-HT_{5B}, or 5-HT₆ receptor.--
- 13. (Amended) The method of claim 7, wherein the 5-HT_{1F} receptor agonist activates the human 5-HT_{1F} receptor at least 100-fold more than it activates any of the human 5-HT_{1A}, 5-HT_{1D}, 5-HT_{2A}, 5-HT_{2C}, 5-HT₃, 5-HT₄, or 5-HT₇

Douglas A. Craig
Serial No.: 09/450,880
Filed: November 29, 1999
Page 3

receptor.--

- 14. (Amended) The method of claim 13, wherein the 5-HT_{1F} receptor agonist additionally activates the human 5-HT_{1F} receptor at least 100-fold more than it activates any of the human 5-HT_{1B}, 5-HT_{1E}, 5-HT_{2B}, 5-HT_{5A}, 5-HT_{5B}, or 5-HT₆ receptor.--
- 19. (Amended) The method of claim 13, wherein the 5-HT_{1F} receptor agonist activates the human 5-HT_{1F} receptor at least 200-fold more than it activates any of the human 5-HT_{1A}, 5-HT_{1D}, 5-HT_{2A}, 5-HT_{2C}, 5-HT₃, 5-HT₄, or 5-HT₇ receptor.--
- 20. (Amended) The method of claim 19, wherein the 5-HT_{1F} receptor agonist additionally activates the human 5-HT_{1F} receptor at least 200-fold more than it activates any of the human 5-HT_{1B}, 5-HT_{1E}, 5-HT_{2B}, 5-HT_{5A}, 5-HT_{5B}, or 5-HT₆ receptor.--

Please add new claims 25 and 26:

- 25. (New) The method of claim 1, wherein the 5-HT_{1F} receptor agonist selectively activates the human 5-HT_{1F} receptor at least ten-fold more than it activates any of the human 5-HT_{1A}, 5-HT_{1D}, 5-HT_{2A}, 5-HT_{2C}, 5-HT₃, 5-HT₄, or 5-HT₇ receptor.--
- 26. (New) The method of claim 1, wherein the 5-HT_{1F} agonist binds to the human 5-HT_{1F} receptor with a K_i value of 7.11 ± 0.76 nM or less.

A marked-up version of the amendments showing the changes made